JPMorgan Chase & Co. Analysts Give BioNTech (NASDAQ:BNTX) a $148.00 Price Target

JPMorgan Chase & Co. set a $148.00 price target on BioNTech (NASDAQ:BNTXGet Rating) in a research report sent to investors on Monday, Borsen Zeitung reports.

A number of other brokerages have also recently issued reports on BNTX. SVB Leerink increased their target price on shares of BioNTech from $223.00 to $224.00 and gave the company an outperform rating in a report on Friday, July 29th. UBS Group set a $168.00 price target on shares of BioNTech in a research report on Tuesday, November 15th. Deutsche Bank Aktiengesellschaft set a $180.00 price target on shares of BioNTech in a research report on Thursday, September 8th. Cowen began coverage on shares of BioNTech in a research report on Wednesday, August 17th. They issued a market perform rating on the stock. Finally, Canaccord Genuity Group lowered their price target on shares of BioNTech from $200.00 to $191.00 and set a buy rating on the stock in a research report on Tuesday, November 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Hold and an average price target of $217.15.

BioNTech Trading Down 1.6 %

Shares of BioNTech stock opened at $156.23 on Monday. BioNTech has a 12-month low of $117.08 and a 12-month high of $374.58. The company has a current ratio of 5.37, a quick ratio of 5.30 and a debt-to-equity ratio of 0.01. The stock has a market cap of $37.91 billion, a PE ratio of 3.53 and a beta of 0.12. The company has a 50-day moving average of $142.25 and a two-hundred day moving average of $149.59.

BioNTech (NASDAQ:BNTXGet Rating) last issued its earnings results on Monday, November 7th. The company reported $6.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.42 by $3.56. BioNTech had a net margin of 55.72% and a return on equity of 66.45%. The company had revenue of $3.46 billion during the quarter, compared to analysts’ expectations of $1.90 billion. During the same period last year, the company posted $14.56 earnings per share. The firm’s quarterly revenue was down 43.1% compared to the same quarter last year. On average, research analysts anticipate that BioNTech will post 34.47 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently made changes to their positions in the stock. International Biotechnology Trust PLC acquired a new position in shares of BioNTech in the 2nd quarter valued at $26,000. Eagle Bay Advisors LLC purchased a new position in shares of BioNTech in the 2nd quarter valued at $33,000. Huntington National Bank purchased a new position in shares of BioNTech in the 3rd quarter valued at $34,000. Heritage Wealth Management LLC purchased a new position in shares of BioNTech in the 2nd quarter valued at $36,000. Finally, Activest Wealth Management raised its stake in shares of BioNTech by 39,000.0% in the 3rd quarter. Activest Wealth Management now owns 391 shares of the company’s stock valued at $53,000 after acquiring an additional 390 shares during the period. Institutional investors and hedge funds own 13.77% of the company’s stock.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Recommended Stories

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.